This move is archived. Current quotes and coverage live on the stock page.
Follow PCRX
PharmaCorp Rx Inc. faced a significant drop in its stock price, closing down 14.66% in the last trading session.
In a challenging day for PharmaCorp Rx Inc. (PCRX.V), the stock tumbled by 14.66%, closing at CA$0.49. This decline raises questions about the company's current standing and future prospects amidst a backdrop of mixed financial results and strategic initiatives.
PharmaCorp Rx Inc.
PCRX.V
PCRX.V
PharmaCorp Rx Inc.
WealthAwesomeMarket cap
$79.78M
52W high
$0.58
52W low
$0.38
1W change
-3.57%
Beta
-3.95
Analyst Price Targets
Based on analyst covering PCRX · as of Sep 17, 2026
Wall Street analysts forecast PCRX stock price to rise 64.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.67
+64.6% Upside
Current Price
C$0.41
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on PCRX's historical volatility
30-Day Vol
43.8%
Annualized
90-Day Vol
51.6%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.34
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.38 | C$0.33 – C$0.44 |
| 60 trading days | C$0.36 | C$0.29 – C$0.45 |
| 90 trading days | C$0.34 | C$0.26 – C$0.44 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should exercise caution as PharmaCorp's recent performance could signal underlying issues despite previous growth announcements.
PharmaCorp's stock plummets 14.66% in one day.
With a market cap of CA$87 million, the stock's volatility raises concerns for investors looking for stability.
Bull case
PharmaCorp has shown some positive momentum in recent quarters, with increasing revenues and a focus on acquisitions that could strengthen its market position.
Bear case
The sharp decline in stock price may reflect investor worries about the company's profitability, highlighted by a negative profit margin of -0.0671 and a lack of recent positive news.
Market Reaction
The decline in PharmaCorp's stock price has raised eyebrows among investors, especially given the company's recent announcements of financial results that showed revenue growth. However, the market's reaction suggests that investors are cautious about the company's ability to maintain profitability, as indicated by its negative profit margin.
Financial Performance Overview
Despite reporting increased revenues in previous quarters, PharmaCorp's financial health remains a concern. The company's P/E ratio is not applicable, and its market cap is currently CA$87 million. Investors may be looking for clearer signs of sustainable profitability and growth before committing more capital.
Looking Ahead
As PharmaCorp Rx Inc. navigates this challenging period, investors should keep an eye on upcoming announcements and strategic moves. The company's focus on acquisitions and leadership changes could provide opportunities for recovery, but the recent stock performance underscores the need for caution.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
